U.S., July 31 -- ClinicalTrials.gov registry received information related to the study (NCT07093814) titled 'A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma' on July 15.
Brief Summary: This study is an open-label, single-arm Phase I/II clinical trial with the primary objective of evaluating the safety, tolerability, and efficacy of VRT106 in patients with recurrent/progressive glioblastoma.
Study Start Date: July 16
Study Type: INTERVENTIONAL
Condition:
Glioblastoma
Intervention:
DRUG: VRT106
VRT106,intravenous
Recruitment Status: RECRUITING
Sponsor: Guangzhou Virotech Pharmaceutical Co., Ltd.
Published by HT Digital Content Services with permission from Health Daily Digest....